This AACE consensus statement was developed by a multidisciplinary task force, which included medical professionals in endocrinology, endocrine surgery, surgical oncology, genetics, and clinical research as well as a patient representative, who conducted a targeted review of the literature to provide practical patient-centered clinical guidance for practitioners who care for individuals with MEN1.

This algorithm provides concise visual guidance in the form of algorithms to assist with clinical decision-making for the management of persons with type 2 diabetes mellitus and related comorbidities.

This new consensus statement summarizes important areas of agreement around the topics of obesity stigma and weight bias from the perspectives of the individual, clinicians, and the healthcare system following the May 2022 AACE Consensus Conference on improving obesity outcomes.

This consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies. The statement summarizes the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies; reviews the clinical presentation of ICI-related endocrinopathies; and discusses the diagnosis and management approaches to endocrinopathies related to ICI therapy.

This consensus statement provides information on novel minimally invasive therapeutic interventions for thyroid malignancies such as percutaneous ethanol injection and thermal ablation. The statement summarizes existing knowledge and provides guidance on indications, techniques, complications, and follow-ups for care of patients with benign and malignant thyroid lesions.

This consensus statement outlines expert opinion and practical information on the evaluation of thyroid nodules, surgical considerations, and postoperative monitoring for children and adolescents with benign and malignant thyroid lesions.

This consensus statement describes the Thyroid Nodule App (termed TNAPP), a novel interactive web-based tool that uses clinical, imaging, cytologic, and molecular marker data to guide clinical decision making to evaluate and manage thyroid nodules.

This consensus statement provides a practical approach to management of patients with newly diagnosed adrenocortical carcinoma, as well as follow-up and management of patients with persistent or recurrent disease, including the management of an adrenal mass, presurgical evaluation, surgical approach, pathologic assessment, and other therapeutic modalities, based on individual patient presentation.

This algorithm for the comprehensive management of dyslipidemia and prevention of cardiovascular disease (CVD) complements the 2017 AACE Guideline for Management of Dyslipidemia and Prevention of Cardiovascular Disease and provides clinicians with a practical guide that considers the whole patient, their spectrum of risks and complications, and evidence-based approaches to treatment.

This consensus statement provides a practical approach to the evaluation of incidentally discovered adrenal masses, presenting five patient case scenarios selected to highlight a unique and relatively characteristic presentation that clinicians may encounter and answering key questions to help guide evaluation, diagnosis, management, and treatment.

This consensus statement identifies common technical errors and issues that can affect DXA report conclusions and provides guidance on how to address those issues to ensure that patients receive appropriate osteoporosis care.

These six case discussions present clinical vignettes to illustrate some of the key recommendations for diagnosis, treatment, and long-term management of transgender children and adults in the Endocrine Society's 2017 guideline, co-sponsored by AACE, on endocrine treatment of persons with gender dysphoria/gender incongruence.

This statement addresses the use of somatostatin-receptor ligands (SRLs) as preoperative therapy for individuals with acromegaly to improve outcomes.

This statement addresses the prevalence of macroprolactin in patients with hyperprolactinemia and macroprolactin’s relevance regarding clinical decision-making about laboratory testing, imaging, and pharmacologic or surgical treatment.

This statement addresses neuroendocrine evaluation, testing, and management of patients with traumatic brain injury‒induced hypopituitarism or those at risk for hypopituitarism.

This statement employs case studies to discuss evaluation, early diagnosis, surgical treatment, and ongoing management of endocrinopathies in patients with multiple endocrine neoplasia, type 2.

Carcinoid tumors, which most commonly originate from the small intestine, are either referred to as small intestinal neuroendocrine tumors or midgut carcinoids. This statement addresses diagnostics and therapeutics for patients with midgut carcinoids and provides an overview of multidisciplinary care to improve quality of life, treatment outcomes, and survival.

This statement addresses incidental detection of pancreatic neuroendocrine tumors, imaging-based characterization for differential diagnoses, prognosis, and appropriate management.

Lipodystrophy is a rare, heterogeneous group of syndromes characterized by the complete or partial loss or absence of subcutaneous adipose tissue. This consensus statement provides an overview of the literature and expert opinion on recognizing lipodystrophy and some potential management strategies.